Explore more publications!
St. Vincent & Grenadines Health Press
Got News to Share?

St. Vincent & Grenadines Health Press: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on St. Vincent & Grenadines Health Press.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 10, 2025

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
December 10, 2025

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Indeterminate GlobeNewswire
Clearmind Medicine Announces 1-for-40 Reverse Share Split
December 10, 2025

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Indeterminate GlobeNewswire
DLH Reports Fiscal 2025 Fourth Quarter Results
December 10, 2025

DLH Reports Fiscal 2025 Fourth Quarter Results

Indeterminate GlobeNewswire
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
December 10, 2025

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

Indeterminate GlobeNewswire
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
December 10, 2025

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Indeterminate GlobeNewswire
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
December 10, 2025

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

Indeterminate GlobeNewswire
Alameda Health System wins equity award for breast cancer screening campaign
December 10, 2025

Alameda Health System wins equity award for breast cancer screening campaign

Indeterminate GlobeNewswire
Allsup Helps Individuals With Crohn’s Disease And Ulcerative Colitis Overcome Barriers To SSDI Benefits
December 10, 2025

Allsup Helps Individuals With Crohn’s Disease And Ulcerative Colitis Overcome Barriers To SSDI Benefits

Indeterminate GlobeNewswire
Vietnam Vet cares for wife and wartime nurse
December 10, 2025

Vietnam Vet cares for wife and wartime nurse

Indeterminate GlobeNewswire
Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer
December 10, 2025

Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer

Indeterminate GlobeNewswire
Tiny Health Celebrates 100,000 Tests Milestone, Expands from Baby Gut Health Pioneer to Longevity Innovator
December 10, 2025

Tiny Health Celebrates 100,000 Tests Milestone, Expands from Baby Gut Health Pioneer to Longevity Innovator

Indeterminate GlobeNewswire
Introducing Tryst Fitness, a New Luxury Gym & Wellness Brand
December 10, 2025

Introducing Tryst Fitness, a New Luxury Gym & Wellness Brand

Indeterminate GlobeNewswire
Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
December 10, 2025

Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Indeterminate GlobeNewswire
Persephone Biosciences Announces Publication in Cell Host & Microbe Highlighting the Critical Need to Restore Bifidobacterium in the Infant Gut Microbiome
December 10, 2025

Persephone Biosciences Announces Publication in Cell Host & Microbe Highlighting the Critical Need to Restore Bifidobacterium in the Infant Gut Microbiome

Indeterminate GlobeNewswire
GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique
December 10, 2025

GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique

Indeterminate GlobeNewswire
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy  
December 10, 2025

GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy  

Indeterminate GlobeNewswire
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
December 10, 2025

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions